Compare Orchid Pharma with NEULAND LABS - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA vs NEULAND LABS - Comparison Results

ORCHID PHARMA     Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA NEULAND LABS ORCHID PHARMA/
NEULAND LABS
 
P/E (TTM) x -126.5 59.3 - View Chart
P/BV x 36.3 4.5 808.5% View Chart
Dividend Yield % 0.0 0.1 -  

Financials

 ORCHID PHARMA   NEULAND LABS
EQUITY SHARE DATA
    ORCHID PHARMA
Sep-13
NEULAND LABS
Mar-20
ORCHID PHARMA/
NEULAND LABS
5-Yr Chart
Click to enlarge
High Rs194754 25.7%   
Low Rs35247 14.2%   
Sales per share (Unadj.) Rs276.5594.5 46.5%  
Earnings per share (Unadj.) Rs-79.212.6 -627.0%  
Cash flow per share (Unadj.) Rs-43.537.0 -117.4%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs53.9553.4 9.7%  
Shares outstanding (eoy) m70.4512.83 549.1%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x0.40.8 49.2%   
Avg P/E ratio x-1.439.6 -3.6%  
P/CF ratio (eoy) x-2.613.5 -19.5%  
Price / Book Value ratio x2.10.9 234.7%  
Dividend payout %015.8 0.0%   
Avg Mkt Cap Rs m8,0676,421 125.6%   
No. of employees `0002.81.3 218.4%   
Total wages/salary Rs m2,5271,236 204.5%   
Avg. sales/employee Rs Th6,956.15,949.4 116.9%   
Avg. wages/employee Rs Th902.5963.8 93.6%   
Avg. net profit/employee Rs Th-1,993.0126.4 -1,576.4%   
INCOME DATA
Net Sales Rs m19,4777,627 255.4%  
Other income Rs m40739 1,048.1%   
Total revenues Rs m19,8847,666 259.4%   
Gross profit Rs m1,1031,019 108.2%  
Depreciation Rs m2,519313 805.4%   
Interest Rs m5,227216 2,422.8%   
Profit before tax Rs m-6,236529 -1,178.4%   
Minority Interest Rs m200-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m5110-   
Tax Rs m-125367 -34.1%   
Profit after tax Rs m-5,580162 -3,442.9%  
Gross profit margin %5.713.4 42.4%  
Effective tax rate %2.069.4 2.9%   
Net profit margin %-28.72.1 -1,348.2%  
BALANCE SHEET DATA
Current assets Rs m11,0145,152 213.8%   
Current liabilities Rs m32,0603,576 896.5%   
Net working cap to sales %-108.120.7 -523.1%  
Current ratio x0.31.4 23.8%  
Inventory Days Days95105 90.3%  
Debtors Days Days3491 36.9%  
Net fixed assets Rs m29,4403,969 741.8%   
Share capital Rs m705129 546.1%   
"Free" reserves Rs m2,0436,971 29.3%   
Net worth Rs m3,8007,100 53.5%   
Long term debt Rs m9,018774 1,165.6%   
Total assets Rs m46,51012,310 377.8%  
Interest coverage x-0.23.5 -5.6%   
Debt to equity ratio x2.40.1 2,177.7%  
Sales to assets ratio x0.40.6 67.6%   
Return on assets %-0.83.1 -24.8%  
Return on equity %-146.92.3 -6,432.6%  
Return on capital %-3.79.5 -39.5%  
Exports to sales %37.90-   
Imports to sales %22.60-   
Exports (fob) Rs m7,378NA-   
Imports (cif) Rs m4,406NA-   
Fx inflow Rs m7,5135,187 144.9%   
Fx outflow Rs m5,6491,593 354.6%   
Net fx Rs m1,8653,594 51.9%   
CASH FLOW
From Operations Rs m1,682573 293.3%  
From Investments Rs m-9,860-487 2,025.6%  
From Financial Activity Rs m6,644-55 -12,123.7%  
Net Cashflow Rs m-1,53533 -4,708.6%  

Share Holding

Indian Promoters % 32.3 36.3 89.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.6 63.7 7.2%  
FIIs % 3.3 0.0 -  
ADR/GDR % 4.6 0.0 -  
Free float % 55.3 63.7 86.8%  
Shareholders   84,811 12,705 667.5%  
Pledged promoter(s) holding % 54.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA With:   ABBOTT INDIA  JUBILANT PHARMOVA   BIOCON   PIRAMAL ENTERPRISES  NATCO PHARMA  

Compare ORCHID PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

6 Reasons Why Sensex Plunged 883 Points Today(Closing)

Indian share markets nosedived and registered sharp losses in today's volatile session following a strong second wave of Covid-19 in the country.

Related Views on News

NEULAND LABS Announces Quarterly Results (3QFY21); Net Profit Up 141.5% (Quarterly Result Update)

Feb 3, 2021 | Updated on Feb 3, 2021

For the quarter ended December 2020, NEULAND LABS has posted a net profit of Rs 267 m (up 141.5% YoY). Sales on the other hand came in at Rs 2 bn (up 20.5% YoY). Read on for a complete analysis of NEULAND LABS's quarterly results.

NEULAND LABS 2019-20 Annual Report Analysis (Annual Result Update)

Sep 2, 2020 | Updated on Sep 2, 2020

Here's an analysis of the annual report of NEULAND LABS for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of NEULAND LABS. Also includes updates on the valuation of NEULAND LABS.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

A Stock with 700% Return Potential Comes with Additional Payoffs(Profit Hunter)

Apr 15, 2021

Narayana Murthy was one of the first unicorn founders to get the backing of this entity...

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

A Unique Sector for Short-Term Profits(Fast Profits Daily)

Apr 12, 2021

This ignored sector could deliver big short-term profits.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA SHARE PRICE


Apr 19, 2021 (Close)

TRACK ORCHID PHARMA

  • Track your investment in ORCHID PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ORCHID PHARMA - DR. REDDYS LAB COMPARISON

COMPARE ORCHID PHARMA WITH

MARKET STATS